phrykt

Moderna, Inc. (MRNA): who owns it and who trades it

As of Nov 16, 2026, MRNA insiders reported 22 open-market sales worth $81.6M and no purchases in the last 12 months, with 99% of the sale value made under pre-set 10b5-1 plans. The largest seller was Stephen Hoge (President), with $45.4M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Moderna

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds and Congress were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns MRNA

776 funds and institutions reported MRNA shares worth $22.6B at the end of Q2 2026, about 81% of the company. The largest holder is FMR LLC (Fidelity) with 13.1%.

Funds and institutions (13F) 81%Everyone else 19%

10 largest owners, by share of the company

FMR LLC (Fidelity)13.1%
BlackRock, Inc.7.7%
Vanguard Capital Management LLC5.8%
Capital World Investors5.6%
Baillie Gifford & Co4.6%
State Street Corp4.0%
Vanguard Portfolio Management LLC3.9%
Geode Capital Management, LLC2.4%
Morgan Stanley2.4%
Theleme Partners LLP2.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)51.86M13.07%$3.6B+14%
BlackRock, Inc.30.60M7.71%$2.1B+3%
Vanguard Capital Management LLC23.21M5.85%$1.6B+1%
Capital World Investors22.28M5.61%$1.6B+19%
Baillie Gifford & Co18.21M4.59%$1.3B-9%
State Street Corp15.73M3.96%$1.1B+6%
Vanguard Portfolio Management LLC15.58M3.93%$1.1B-0%
Geode Capital Management, LLC9.71M2.45%$679M+3%
Morgan Stanley9.54M2.40%$668M+13%
Theleme Partners LLP8.06M2.03%$564M+0%
Two Sigma Investments, LP7.19M1.81%$504M-21%
Invesco Ltd.5.78M1.46%$405M+21%
T. Rowe Price Associates5.59M1.41%$391M+657%
Charles Schwab Investment Management Inc4.84M1.22%$339M+2%
Sixth Street Partners Management Company, L.P.4.84M1.22%$339M–
Goldman Sachs Group Inc4.67M1.18%$327M-29%
Flagship Pioneering, LLC4.63M1.17%$324MNo change
UBS Group AG4.46M1.12%$313M+1%
BNP Paribas Financial Markets4.38M1.10%$307M+1%
Norges Bank3.03M0.76%$212M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, MRNA insiders reported $0 of open-market purchases and $81.6M of sales. 99% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$81.6M
22 trades, 6 people
Sales under a 10b5-1 plan
99%
Share of sale value
Latest trade
Oct 15, 2026
Filed Oct 16, 2026

Purchases and sales by month

$28.7M$28.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 15, 2026Stephen HogePresidentSale plan39,145$220.72$8.6MForm 4
Oct 14, 2026Stephen HogePresidentSale plan38,774$213.47$8.3MForm 4
Oct 14, 2026Stephen HogePresidentSale plan450$214.15$96.4KForm 4
Sep 15, 2026Stephen HogePresidentSale plan40,281$146.07$5.9MForm 4
Sep 14, 2026Stephen HogePresidentSale plan40,294$144.13$5.8MForm 4
Sep 10, 2026James M MockCFOSale plan15,000$134.49$2MForm 4
Sep 10, 2026James M MockCFOSale plan19,836$134.49$2.7MForm 4
Sep 1, 2026Shannon Thyme KlingerChief Legal OfficerSale plan3,471$139.95$486KForm 4
Aug 5, 2026Stephane BancelCEOSale plan124,838$56.96$7.1MForm 4
Aug 5, 2026Stephane BancelCEOSale plan187,044$58.79$11MForm 4
Aug 5, 2026Stephane BancelCEOSale plan147,473$56.21$8.3MForm 4
Aug 5, 2026Stephane BancelCEOSale plan39,891$58.12$2.3MForm 4
Jul 15, 2026Stephen HogePresidentSale plan53,336$67.60$3.6MForm 4
Jun 15, 2026Stephen HogePresidentSale plan53,336$51.37$2.7MForm 4
Jun 4, 2026Shannon Thyme KlingerChief Legal OfficerSale plan3,471$50.00$174KForm 4
May 21, 2026Noubar AfeyanDirectorSale9,263$46.84$434KForm 4
May 15, 2026Stephen HogePresidentSale plan53,336$48.40$2.6MForm 4
May 1, 2026Abbas HussainDirectorSale plan5,682$46.63$265KForm 4
Mar 2, 2026Shannon Thyme KlingerChief Legal OfficerSale plan13,885$52.29$726KForm 4
Feb 23, 2026Stephen HogePresidentSale plan160,009$48.84$7.8MForm 4
Dec 11, 2025Noubar AfeyanDirectorSale23,853$29.49$703KForm 4
Dec 9, 2025Abbas HussainDirectorSale plan504$27.60$13.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Stephen HogePresident–$45.4MOct 15, 2026
Stephane BancelChief Executive Officer, Director–$28.7MAug 5, 2026
James M MockChief Financial Officer–$4.7MSep 10, 2026
Shannon Thyme KlingerChief Legal Officer–$1.4MSep 1, 2026
Noubar AfeyanDirector–$1.1MMay 21, 2026
Abbas HussainDirector–$279KMay 1, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MRNA short interest

Moderate short interest. 8.2% of MRNA shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 43%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 33.19M MRNA shares were sold short, 8.2% of the shares outstanding, up 1.8% from the report before. At the average daily volume of 18.84M shares, buying them all back would take about 1.8 trading days (days to cover).

Shares short, % of all shares

8.20%May 15Oct 3015.8%

Days to cover

1.8May 15Oct 3014.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202633.19M8.20%+2%18.84M1.8
Oct 15, 202632.60M8.17%+6%18.29M1.8
Sep 30, 202630.86M7.73%-6%16.89M1.8
Sep 15, 202632.87M8.23%-16%13.01M2.5
Aug 31, 202639.15M9.81%-26%50.16M1.0
Aug 14, 202652.81M13.23%+6%5.77M9.2
Jul 31, 202649.77M12.47%-5%4.87M10.2
Jul 15, 202652.40M13.21%-1%8.63M6.1
Jun 30, 202653.19M13.40%-9%11.53M4.6
Jun 15, 202658.66M14.79%+1%5.60M10.5
May 29, 202657.81M14.57%-0%4.71M12.3
May 15, 202658.07M14.64%-0%10.32M5.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded MRNA

Since Nov 17, 2024, 4 members of Congress reported 3 purchases and 4 sales of MRNA. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Oct 20, 2026, reported Nov 10, 2026.

Purchases 3Sales 4

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Oct 20, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfNov 10, 2026Report
Sep 24, 2026Maria Elvira Salazar (R-FL)Partial sale$1K–$15KSelfOct 7, 2026Report
Aug 19, 2026Maria Elvira Salazar (R-FL)Partial sale$1K–$15KSelfSep 9, 2026Report
Aug 19, 2026Maria Elvira Salazar (R-FL)Purchase$1K–$15KSelfSep 9, 2026Report
Apr 8, 2025Robert P. Bresnahan, Jr. (R-PA)Sale$1K–$15KSelfMay 8, 2025Report
Feb 25, 2025Robert P. Bresnahan, Jr. (R-PA)Purchase$1K–$15KSelfMar 27, 2025Report
Jan 15, 2025Julie Johnson (D-TX)Sale$1K–$15KJointFeb 12, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Moderna company events

Moderna filed 14 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 6, 2026.

  1. Nov 6, 2026ResultsReleased financial results. Filing
  2. Sep 30, 2026LeadershipModerna, Inc. announced the appointment of Juan Andres as its Chief Operating Officer effective October 5, 2026. Filing
  3. Sep 1, 2026AgreementModerna, Inc. completed its previously announced private offering of $3 billion of 0.00% Convertible Senior Notes due 2032, including the exercise in full of the initial purchasers’ option to purchase up to an additional $400 million of the Notes. Filing
  4. Jul 31, 2026ResultsReleased financial results. Filing
  5. Jul 8, 2026LeadershipThe Board of Directors of Moderna, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Michael McDonnell to the Board, effective July 8, 2026. Filing
  6. May 11, 2026VoteReported shareholder vote results. Filing
  7. May 1, 2026ResultsReleased financial results. Filing
  8. Mar 5, 2026AgreementModerna, Inc. and ModernaTX, Inc. (together with the Company, “Moderna”) and Arbutus Biopharma Corporation, Genevant Sciences GmbH, and, solely for certain purposes, Genevant Sciences Ltd., entered into a settlement agreement to resolve all patent infringement litigation between Moderna and… Filing
  9. Feb 13, 2026ResultsReleased financial results. Filing
  10. Feb 11, 2026AnnouncementThe FDA's Center for Biologics Evaluation and Research notified the Company that it will not initiate a review of the biologics license application for the Company's investigational influenza vaccine, mRNA-1010, and has issued a Refusal-to-File letter. Filing
  11. Jan 12, 2026ResultsReleased financial results. Filing
  12. Jan 5, 2026AnnouncementShared information with investors. Filing
  13. Nov 24, 2025AgreementModerna, Inc. entered into a Credit and Guaranty Agreement, among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent. Filing
  14. Nov 20, 2025AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Moderna financials

Famous investors that hold MRNA

5 of the 50 well-known investors we track reported holding MRNA in their latest 13F filing. The largest position is Israel Englander's, worth $750M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20263.89M$750M0.6%+788%
Ken Griffin · Citadel AdvisorsQ3 2026116,160$22.4M0.0%-61%
Steve Cohen · Point72 Asset ManagementQ3 2026108,615$20.9M0.0%New
Ray Dalio · Bridgewater AssociatesQ3 202672,342$13.9M0.1%+528%
Ken Fisher · Fisher Asset ManagementQ3 20269,154$1.8M0.0%-16%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named MRNA in the last 120 days.

FiledHolderFormStake
Nov 5, 2026FMR LLC13G/A14.8%
Nov 5, 2026FMR LLC13G/A14.8%

Questions about Moderna, Inc. (MRNA) stock

Who owns the most MRNA stock?

The largest reported owner of Moderna, Inc. (MRNA) is FMR LLC (Fidelity), with 13.1% of the company. In total, 776 funds and institutions reported holding MRNA at the end of Q2 2026, together about 81% of the shares. See the largest owners.

Are MRNA insiders buying or selling?

In the last 12 months, MRNA insiders reported no open-market purchases and 22 sales worth $81.6M. The latest trade was on Oct 15, 2026. See every trade.

What is the short interest in MRNA?

As of Oct 30, 2026, 33.19M MRNA shares were sold short, 8.2% of the shares outstanding, up 1.8% from the report before. At the average daily volume of 18.84M shares, buying them all back would take about 1.8 trading days (days to cover). See the history.

Have members of Congress traded MRNA?

Yes. 4 members of Congress reported 3 purchases and 4 sales of MRNA since Nov 17, 2024. The latest was reported on Nov 10, 2026. See the trades.

Which famous investors hold MRNA?

5 of the 50 well-known investors we track reported MRNA in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $750M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.